✦ LIBER ✦

Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease

✍ Scribed by Derek H. Tang; Edward P. Armstrong; Jeannie K. Lee

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PSS25 COST-EFFECTIVENESS OF BIOLOGIC TRE

✍ Carretero, G; Moreno, JC; Notario, J; Silvestre, JF; López-Belmonte, JL; Giménez 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Ustekinumab for Moderate-to-Severe Crohn

✍ Gupta Konijeti, Gauree; Chan, Andrew T. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Cost-Effectiveness of Sequences of Biolo

✍ Asseburg, C.; Valgardsson, S.; Soini, E.J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

PGI7 COST-EFFECTIVENESS ANALYSIS OF ADAL

✍ S Johnson; A Kaltenboeck; C Horn; P Mulani; S Majethia; J Chao 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

Natalizumab promising for moderately to

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

PUK33 Cost-Utility Analysis of Alternati

✍ Z. Qureshi; C. Bennett 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB